MediWound Ltd. (MDWD) Now Covered by Aegis
Analysts at Aegis started coverage on shares of MediWound Ltd. (NASDAQ:MDWD) in a report released on Monday. The firm set a “buy” rating and a $11.00 price target on the biopharmaceutical company’s stock. Aegis’ price objective would indicate a potential upside of 105.61% from the company’s current price.
Other research analysts have also issued research reports about the company. Zacks Investment Research lowered MediWound from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Wells Fargo & Co. began coverage on MediWound in a research report on Wednesday, August 17th. They set an “outperform” rating and a $14.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $13.25.
MediWound (NASDAQ:MDWD) opened at 5.35 on Monday. The company’s market capitalization is $117.01 million. The company has a 50-day moving average price of $6.09 and a 200 day moving average price of $7.29. MediWound has a 12 month low of $5.00 and a 12 month high of $10.31.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.26). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.61 million. MediWound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The business’s quarterly revenue was up 420.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS. On average, equities research analysts forecast that MediWound will post ($0.99) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “MediWound Ltd. (MDWD) Now Covered by Aegis” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/30/mediwound-ltd-mdwd-now-covered-by-aegis.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock worth $8,431,000 after buying an additional 100,723 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of MediWound during the second quarter worth approximately $13,302,000. United Services Automobile Association raised its position in shares of MediWound by 125.9% in the second quarter. United Services Automobile Association now owns 123,440 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 68,800 shares in the last quarter. Wells Fargo & Company MN purchased a new position in shares of MediWound during the third quarter worth approximately $202,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of MediWound during the third quarter worth approximately $116,000. 27.27% of the stock is currently owned by institutional investors and hedge funds.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.